US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections
AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...
AbbVie gets FDA approval for antibiotic treatment Emblaveo (update)
AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...
Senators warn FDA about Super Bowl commercial believed to mislead patients
A group of Senators has warned the FDA about an ad expected to air during Sunday’s big game that they believe misleads ...
Healio7h
FDA approves Emblaveo for complicated intra-abdominal infections
The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.
The American Journal of Managed Care5h
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”
Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...
Hosted on MSN7h
Newly FDA-approved non-opioid painkiller is first of its kind in over 20 years
For the first time in 20 years, the Food and Drug Administration has approved a new pharmaceutical approach to treating pain.
AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo
AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.
Hims & Hers responds to controversy over Super Bowl weight loss drug commercial: 'We're calling for change'
Hims & Hers believes that is where the controversy lies. “We called on the industry and said that they need to change — and ...
Weight Loss Drug Super Bowl Ad Raises Questions About Compounded Vs. Branded Meds
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
Crain's Chicago Business8h
AbbVie gets FDA OK on antibiotic therapy that fights resistant bacteria
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
Delcath Systems: Strong Position In Metastatic Uveal Melanoma, But Broader Growth Challenges Ahead
Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to read my analysis of DCTH stock.